^
    Back
    Association details:
    Biomarker:ER positive
    Cancer:HER2 Negative Breast Cancer
    Drug:fulvestrant (Selective estrogen receptor degrader)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Estrogen Receptor Positive Breast Cancer)
    New
    Excerpt:
    Fulvestrant is indicated for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women…
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    500mg Fulvestrant Versus Exemestane in MBC

    Excerpt:
    ...Diagnosed with ER/PR+，HER2- Metastatic Breast Cancer...
    Trial ID:
    NCT03575260
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Japanese Society of Internal Medicine
    Title:

    Factors associated with overall survival after recurrence in patients with ER-positive/HER2-negative postmenopausal breast cancer: an ad hoc analysis of the JBCRG-C06 Safari study Get access Arrow

    Published date:
    03/16/2022
    Excerpt:
    ...multicenter study in which 1072 consecutive cases of estrogen receptor-positive advanced breast cancer treated using 500 mg fulvestrant...The overall survival after recurrence in patients with estrogen receptor-positive human epidermal growth factor receptor 2 negative recurrent breast cancer...Multivariate analysis revealed that favorable overall survival (median, 6.4 years) was significantly correlated with long time from recurrence to fulvestrant use (≥3 years)...
    DOI:
    https://doi.org/10.1093/jjco/hyac022
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2021
    Title:

    235P - Efficacy and safety of first-line therapy with fulvestrant or exemestane for postmenopausal ER+/HER2- advanced breast cancer patients after adjuvant nonsteroidal aromatase inhibitor treatment: A randomized, open-label, multicenter study

    Published date:
    09/13/2021
    Excerpt:
    In this randomized, open-label, multi-center, parallel-group study, postmenopausal women with recurrent ER+/HER2- advanced breast cancer receiving at least 2 years NSAIs as adjuvant treatment were randomly assigned to receive fulvestrant (500 mg on days 0, 14, and 28 and every 28 (± 3) days thereafter) or exemestane (25 mg daily)....Fulvestrant 500 mg was associated with a statistically significant increase in PFS compared with exemestane and was generally well tolerated.
    Trial ID:
    FRIEND
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Oncologist
    Title:

    A Phase II Study of Fulvestrant 500 mg as Maintenance Therapy in HR-Positive, HER2-Negative Patients with Advanced Breast Cancer After First-Line Chemotherapy

    Published date:
    11/27/2020
    Excerpt:
    The CBR since commencing fulvestrant maintenance therapy was 76% (95% confidence interval [CI], 63%-86%), and ORR was 14% (95% CI, 6%-25%); eight patients achieved partial response….Fulvestrant 500 mg is a feasible and promising hormonal maintenance strategy in ER-positive/HER2-negative advanced breast cancer patients who have no disease progression after first-line chemotherapy.
    DOI:
    10.1002/onco.13614
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Clin Breast Cancer
    Title:

    Fulvestrant 500 mg Versus Exemestane in Postmenopausal Women With Metastatic Breast Cancer Resistant to Adjuvant Nonsteroidal Aromatase Inhibitors in Clinical Practice: A Multicenter Retrospective Study

    Published date:
    02/07/2019
    Excerpt:
    Fulvestrant 500 mg showed better efficacy than exemestane in first-line therapy for MBC of ER+ postmenopausal women after failure of adjuvant NSAI treatment.
    DOI:
    10.1016/j.clbc.2019.01.015
    Trial ID:
    NCT03575260